Clinical Trial

CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT

Study acronym: CD45RADLIHaplo
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-04; most recent amendment 2025-04-23.
Trial Details
NCT Number NCT05943067
Lead Sponsor University Hospital Tuebingen
Conditions Hematologic Malignancy
Enrollment 60 participants
Start Date 2023-04-27
Primary Completion 2028-01 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-27